The use of inhaled corticosteroids and the risk of adrenal insufficiency
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Adrenal insufficiency is a potential complication of therapy with an inhaled corticosteroid (ICS). Although prior studies found the highest risk of adrenal insufficiency with fluticasone, a more potent ICS, these results might be explained by a channelling bias and concomitant exposure to oral corticosteroids. We re-examined the relationship between the use of ICSs and adrenal insufficiency by using a cohort of patients treated for respiratory conditions during 1990-2005, identified in the healthcare databases from the province of Quebec, Canada, with follow-up until 2007. A nested case-control analysis was performed within this cohort. Cases of adrenal insufficiency were matched with up to 10 controls. 392 cases were identified (incidence rate 1.1 per 10 000 person-years). Although the rate of adrenal insufficiency was not significantly higher among all current users of ICSs, patients receiving the highest dosages showed a greater risk (OR 1.84, 95% CI 1.16-2.90). Consistently, an increased risk was estimated for the highest tertile of ICS dose (OR 1.90, 95% CI 1.07-3.37) cumulated in the year before the event. ICS at high doses appear to be a significant independent risk factor for adrenal insufficiency. Physicians prescribing ICS at such dosages should be sensitive to the signs and symptoms of adrenal insufficiency in their patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A Canadian study found only 392 hospital admissions due to glucocorticoid-induced adrenal insufficiency over a 15-year period among adults receiving inhaled glucocorticoids (105).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [105]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients using higher daily doses and cumulative yearly doses had an almost twofold higher risk of hospital admission than those with lower exposure (105).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [105]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma
Program, P., & theDiagnosis, T. E. P. O. (1997) · Cited by 4,926
Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma
Suissa, S., Ernst, P., Benayoun, S., Baltzan, M., & Cai, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430504 · Cited by 1,100
Self-citationSystemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Lipworth, B. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.9.941 · Cited by 918
Oelkers, W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351607 · Cited by 737
Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.
Boulet, L. P., Becker, A. B., Bérubé, D., Beveridge, R., & Ernst, P. (1999) · Europe PMC (PubMed Central) · Cited by 536
Self-citationStatistics in Epidemiology: The Case-Control Study
Breslow, N. E. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476660 · Cited by 463
Erichsen, M. M., Løvås, K., Skinningsrud, B., Wolff, A. B., Undlien, D. E., Svartberg, J., Fougner, K. J., Berg, T. J., Bollerslev, J., Mella, B., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1368 · Cited by 422
Ernst, P., Gonzalez, A. V., Brassard, P., & Suissa, S. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200611-1630oc · Cited by 389
Self-citationSystemic side effects of inhaled corticosteroids in patients with asthma
Dahl, R. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2005.11.020 · Cited by 359
Predisposing Factors for Adrenal Insufficiency
Bornstein, S. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804635 · Cited by 356
Research works printed but not linked: 1
- Schimmer BP Parker KL . Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs: inhibitors of synthesis and action of adrenocortical hormones. In: Brunton LL , ed. Goodman and Gilman’s Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 2006.
Cited by
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Inhaled corticosteroids in COPD: the clinical evidence
Ernst, P., Saad, N., & Suissa, S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00128914 · Cited by 161
“…administrative databases, we again found a large excess risk of adrenal insufficiency related to the cumulative dose of oral corticosteroids, but again a suggestion of a significant independent risk with daily doses of ICS equivalent to fluticasone ⩾ 1000 µg (RR 1.84, 95% CI 1.16 – 2.90) [95].”
BackgroundInfluentialSelf-citationGlucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 154
Inhaled Corticosteroids in Lung Diseases
Raissy, H., Kelly, H. W., Harkins, M. S., & Szefler, S. J. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201210-1853pp · Cited by 134
“Patients exposed to high doses of ICSs (based on guidelines, Table 2) should have their HPA-axis monitored (65).”
Background
Metadata
- Authors
- Lapi, F., Kezouh, A., Suissa, S., & Ernst, P.
- Affiliations
- Jewish General Hospital (CA)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2012-10-11
- Volume
- 42
- Issue
- 1
- Pages
- 79-86
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2118348838
- Cited by
- 63
- References
- 34
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 11 · 2023: 1 · 2022: 5 · 2021: 6 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 5 · 2016: 4 · 2015: 7 · 2014: 5 · 2013: 4
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- inhaled corticosteroids, adrenal insufficiency, fluticasone, adverse drug reactions, respiratory diseases, oral corticosteroids
- MeSH terms
- Administration, Inhalation, Administration, Oral, Adolescent, Adrenal Cortex Hormones, Adrenal Insufficiency, Adult, Aged, Aged, 80 and over, Bronchodilator Agents, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Quebec, Risk, Risk Factors, Cohort Studies, Odds Ratio, Case-Control Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The use of inhaled corticosteroids and the risk of adrenal insufficiency. https://app.cochat.ai/papers/10.1183/09031936.00080912
- The paper
- Lapi, F., Kezouh, A., Suissa, S., & Ernst, P. (2013). The use of inhaled corticosteroids and the risk of adrenal insufficiency. European Respiratory Journal. https://doi.org/10.1183/09031936.00080912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.